Single-nucleotide polymorphism of CYP3A5 impacts the exposure to tacrolimus in pediatric renal transplant recipients: A pharmacogenetic substudy of the TWIST trial

Heiko Billing, Britta Höcker, Alexander Fichtner, Rita Van Damme-Lombaerts, Styrbjorn Friman, Jenö Jaray, Karel Vondrak, E. Sárváry, Luca Dello Strologo, Michael Oellerich, Nicolas Von Ahsen, Burkhard Tönshoff

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: The pharmacokinetics of tacrolimus (TAC) and mycophenolic acid (MPA) are highly variable. An impact of singlenucleotide polymorphisms (SNPs) of the genes coding for enzymes and transporters involved in the pharmacokinetics of TAC and/or MPA is intuitively conceivable. Accordingly, we sought to analyze the influence of different SNPs on TAC and MPA exposure in pediatric renal transplant recipients. Methods: A subpopulation of 37 patients (median age: 12.8 years, range 2.2-18.3 years) participating in the TWIST study was included in the analysis of SNPs of CYP3A5, ABCB1 (MDR1), ABCG2, SLCO1B3 (coding for OATP2), ABCC2 (coding for cMOAT), and UGT1/2. TAC trough concentrations and abbreviated area under the concentration-time curves (AUC) of MPA were measured on days 7, 28, 91, and 183 after transplant. Both of these were adjusted to the respective dose the patient received. Results: The allele frequencies of analyzed SNP's were comparable to those reported previously for white populations. Doseadjusted trough concentrations of TAC were approximately 60% lower in patients with the CYP3A5∗1/∗3 allele as compared with the CYP3A5∗3/∗3 allele (P = 0.004). Steroid-free patients in CYP3A5∗3/∗3 and CYP3A5∗1/∗3 carrier subgroups had comparable dose-adjusted TAC concentrations to the subgroup on steroids (P = 0.13). Patients younger than 10 years had a significantly lower median dose-adjusted TAC C0 concentration than patients older than 10 years; this age effect was comparable in heterozygous and homozygous CYP3A5 carriers as well as in patients on and off steroid medication. As for MPA, the genetic variability of transporters or enzymes had no impact on dose-adjusted MPA-AUC due to the low allele frequencies. Patients off steroids had a higher dose-adjusted MPA-AUC (0.18 mg·h/L per mg/m2, 0.012-0.27) compared with patients on steroids (0.12 mg·h·L-1·mg-1, 0.09-0.19; P = 0.04). Conclusions: Genetic variability of CYP3A5 has an impact on TAC metabolism in pediatric renal transplant recipients, contributing partly to the variability of TAC exposure. Therefore, adjusting initial TAC dosing to the genotype of CYP3A5 might be of clinical benefit.

Original languageEnglish
Pages (from-to)21-28
Number of pages8
JournalTherapeutic Drug Monitoring
Volume39
Issue number1
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Cytochrome P-450 CYP3A
Pharmacogenetics
Tacrolimus
Mycophenolic Acid
Single Nucleotide Polymorphism
Pediatrics
Kidney
Steroids
Gene Frequency
Pharmacokinetics
Alleles
Transplant Recipients
Enzymes
Genotype
Transplants

Keywords

  • Immunosuppressive therapy
  • MPA
  • Pediatric renal transplantation
  • Pharmacogenetics
  • Tacrolimus

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Single-nucleotide polymorphism of CYP3A5 impacts the exposure to tacrolimus in pediatric renal transplant recipients : A pharmacogenetic substudy of the TWIST trial. / Billing, Heiko; Höcker, Britta; Fichtner, Alexander; Van Damme-Lombaerts, Rita; Friman, Styrbjorn; Jaray, Jenö; Vondrak, Karel; Sárváry, E.; Strologo, Luca Dello; Oellerich, Michael; Von Ahsen, Nicolas; Tönshoff, Burkhard.

In: Therapeutic Drug Monitoring, Vol. 39, No. 1, 01.01.2017, p. 21-28.

Research output: Contribution to journalArticle

Billing, H, Höcker, B, Fichtner, A, Van Damme-Lombaerts, R, Friman, S, Jaray, J, Vondrak, K, Sárváry, E, Strologo, LD, Oellerich, M, Von Ahsen, N & Tönshoff, B 2017, 'Single-nucleotide polymorphism of CYP3A5 impacts the exposure to tacrolimus in pediatric renal transplant recipients: A pharmacogenetic substudy of the TWIST trial', Therapeutic Drug Monitoring, vol. 39, no. 1, pp. 21-28. https://doi.org/10.1097/FTD.0000000000000361
Billing, Heiko ; Höcker, Britta ; Fichtner, Alexander ; Van Damme-Lombaerts, Rita ; Friman, Styrbjorn ; Jaray, Jenö ; Vondrak, Karel ; Sárváry, E. ; Strologo, Luca Dello ; Oellerich, Michael ; Von Ahsen, Nicolas ; Tönshoff, Burkhard. / Single-nucleotide polymorphism of CYP3A5 impacts the exposure to tacrolimus in pediatric renal transplant recipients : A pharmacogenetic substudy of the TWIST trial. In: Therapeutic Drug Monitoring. 2017 ; Vol. 39, No. 1. pp. 21-28.
@article{a3fe01c89a7a48e991ee4dcfe4a62ea5,
title = "Single-nucleotide polymorphism of CYP3A5 impacts the exposure to tacrolimus in pediatric renal transplant recipients: A pharmacogenetic substudy of the TWIST trial",
abstract = "Background: The pharmacokinetics of tacrolimus (TAC) and mycophenolic acid (MPA) are highly variable. An impact of singlenucleotide polymorphisms (SNPs) of the genes coding for enzymes and transporters involved in the pharmacokinetics of TAC and/or MPA is intuitively conceivable. Accordingly, we sought to analyze the influence of different SNPs on TAC and MPA exposure in pediatric renal transplant recipients. Methods: A subpopulation of 37 patients (median age: 12.8 years, range 2.2-18.3 years) participating in the TWIST study was included in the analysis of SNPs of CYP3A5, ABCB1 (MDR1), ABCG2, SLCO1B3 (coding for OATP2), ABCC2 (coding for cMOAT), and UGT1/2. TAC trough concentrations and abbreviated area under the concentration-time curves (AUC) of MPA were measured on days 7, 28, 91, and 183 after transplant. Both of these were adjusted to the respective dose the patient received. Results: The allele frequencies of analyzed SNP's were comparable to those reported previously for white populations. Doseadjusted trough concentrations of TAC were approximately 60{\%} lower in patients with the CYP3A5∗1/∗3 allele as compared with the CYP3A5∗3/∗3 allele (P = 0.004). Steroid-free patients in CYP3A5∗3/∗3 and CYP3A5∗1/∗3 carrier subgroups had comparable dose-adjusted TAC concentrations to the subgroup on steroids (P = 0.13). Patients younger than 10 years had a significantly lower median dose-adjusted TAC C0 concentration than patients older than 10 years; this age effect was comparable in heterozygous and homozygous CYP3A5 carriers as well as in patients on and off steroid medication. As for MPA, the genetic variability of transporters or enzymes had no impact on dose-adjusted MPA-AUC due to the low allele frequencies. Patients off steroids had a higher dose-adjusted MPA-AUC (0.18 mg·h/L per mg/m2, 0.012-0.27) compared with patients on steroids (0.12 mg·h·L-1·mg-1, 0.09-0.19; P = 0.04). Conclusions: Genetic variability of CYP3A5 has an impact on TAC metabolism in pediatric renal transplant recipients, contributing partly to the variability of TAC exposure. Therefore, adjusting initial TAC dosing to the genotype of CYP3A5 might be of clinical benefit.",
keywords = "Immunosuppressive therapy, MPA, Pediatric renal transplantation, Pharmacogenetics, Tacrolimus",
author = "Heiko Billing and Britta H{\"o}cker and Alexander Fichtner and {Van Damme-Lombaerts}, Rita and Styrbjorn Friman and Jen{\"o} Jaray and Karel Vondrak and E. S{\'a}rv{\'a}ry and Strologo, {Luca Dello} and Michael Oellerich and {Von Ahsen}, Nicolas and Burkhard T{\"o}nshoff",
year = "2017",
month = "1",
day = "1",
doi = "10.1097/FTD.0000000000000361",
language = "English",
volume = "39",
pages = "21--28",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Single-nucleotide polymorphism of CYP3A5 impacts the exposure to tacrolimus in pediatric renal transplant recipients

T2 - A pharmacogenetic substudy of the TWIST trial

AU - Billing, Heiko

AU - Höcker, Britta

AU - Fichtner, Alexander

AU - Van Damme-Lombaerts, Rita

AU - Friman, Styrbjorn

AU - Jaray, Jenö

AU - Vondrak, Karel

AU - Sárváry, E.

AU - Strologo, Luca Dello

AU - Oellerich, Michael

AU - Von Ahsen, Nicolas

AU - Tönshoff, Burkhard

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: The pharmacokinetics of tacrolimus (TAC) and mycophenolic acid (MPA) are highly variable. An impact of singlenucleotide polymorphisms (SNPs) of the genes coding for enzymes and transporters involved in the pharmacokinetics of TAC and/or MPA is intuitively conceivable. Accordingly, we sought to analyze the influence of different SNPs on TAC and MPA exposure in pediatric renal transplant recipients. Methods: A subpopulation of 37 patients (median age: 12.8 years, range 2.2-18.3 years) participating in the TWIST study was included in the analysis of SNPs of CYP3A5, ABCB1 (MDR1), ABCG2, SLCO1B3 (coding for OATP2), ABCC2 (coding for cMOAT), and UGT1/2. TAC trough concentrations and abbreviated area under the concentration-time curves (AUC) of MPA were measured on days 7, 28, 91, and 183 after transplant. Both of these were adjusted to the respective dose the patient received. Results: The allele frequencies of analyzed SNP's were comparable to those reported previously for white populations. Doseadjusted trough concentrations of TAC were approximately 60% lower in patients with the CYP3A5∗1/∗3 allele as compared with the CYP3A5∗3/∗3 allele (P = 0.004). Steroid-free patients in CYP3A5∗3/∗3 and CYP3A5∗1/∗3 carrier subgroups had comparable dose-adjusted TAC concentrations to the subgroup on steroids (P = 0.13). Patients younger than 10 years had a significantly lower median dose-adjusted TAC C0 concentration than patients older than 10 years; this age effect was comparable in heterozygous and homozygous CYP3A5 carriers as well as in patients on and off steroid medication. As for MPA, the genetic variability of transporters or enzymes had no impact on dose-adjusted MPA-AUC due to the low allele frequencies. Patients off steroids had a higher dose-adjusted MPA-AUC (0.18 mg·h/L per mg/m2, 0.012-0.27) compared with patients on steroids (0.12 mg·h·L-1·mg-1, 0.09-0.19; P = 0.04). Conclusions: Genetic variability of CYP3A5 has an impact on TAC metabolism in pediatric renal transplant recipients, contributing partly to the variability of TAC exposure. Therefore, adjusting initial TAC dosing to the genotype of CYP3A5 might be of clinical benefit.

AB - Background: The pharmacokinetics of tacrolimus (TAC) and mycophenolic acid (MPA) are highly variable. An impact of singlenucleotide polymorphisms (SNPs) of the genes coding for enzymes and transporters involved in the pharmacokinetics of TAC and/or MPA is intuitively conceivable. Accordingly, we sought to analyze the influence of different SNPs on TAC and MPA exposure in pediatric renal transplant recipients. Methods: A subpopulation of 37 patients (median age: 12.8 years, range 2.2-18.3 years) participating in the TWIST study was included in the analysis of SNPs of CYP3A5, ABCB1 (MDR1), ABCG2, SLCO1B3 (coding for OATP2), ABCC2 (coding for cMOAT), and UGT1/2. TAC trough concentrations and abbreviated area under the concentration-time curves (AUC) of MPA were measured on days 7, 28, 91, and 183 after transplant. Both of these were adjusted to the respective dose the patient received. Results: The allele frequencies of analyzed SNP's were comparable to those reported previously for white populations. Doseadjusted trough concentrations of TAC were approximately 60% lower in patients with the CYP3A5∗1/∗3 allele as compared with the CYP3A5∗3/∗3 allele (P = 0.004). Steroid-free patients in CYP3A5∗3/∗3 and CYP3A5∗1/∗3 carrier subgroups had comparable dose-adjusted TAC concentrations to the subgroup on steroids (P = 0.13). Patients younger than 10 years had a significantly lower median dose-adjusted TAC C0 concentration than patients older than 10 years; this age effect was comparable in heterozygous and homozygous CYP3A5 carriers as well as in patients on and off steroid medication. As for MPA, the genetic variability of transporters or enzymes had no impact on dose-adjusted MPA-AUC due to the low allele frequencies. Patients off steroids had a higher dose-adjusted MPA-AUC (0.18 mg·h/L per mg/m2, 0.012-0.27) compared with patients on steroids (0.12 mg·h·L-1·mg-1, 0.09-0.19; P = 0.04). Conclusions: Genetic variability of CYP3A5 has an impact on TAC metabolism in pediatric renal transplant recipients, contributing partly to the variability of TAC exposure. Therefore, adjusting initial TAC dosing to the genotype of CYP3A5 might be of clinical benefit.

KW - Immunosuppressive therapy

KW - MPA

KW - Pediatric renal transplantation

KW - Pharmacogenetics

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=85027926967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027926967&partnerID=8YFLogxK

U2 - 10.1097/FTD.0000000000000361

DO - 10.1097/FTD.0000000000000361

M3 - Article

C2 - 28030534

AN - SCOPUS:85027926967

VL - 39

SP - 21

EP - 28

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 1

ER -